Ginsenoside F1
Based on 1 publication(s) in Google Scholar
Ginsenoside F1, an enzymatically modified derivative of Ginsenoside Rg1, demonstrates competitive inhibition of CYP3A4 activity and weaker inhibition of CYP2D6 activity.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.86%
- No. CAS: 53963-43-2
- Fòrmula: C36H62O9
- Peso molecular:638.87
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Glycoside Compound Library
HY-L042
-
Oxygen Sensing Compound Library
HY-L045
-
Medicine Food Homology Compound Library
HY-L055
-
Terpenoids Library
HY-L056
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Mitochondria-Targeted Compound Library
HY-L089
-
Food-Sourced Compound Library
HY-L094
-
Anti-Cancer Natural Product Library
HY-L107
-
Plant-Sourced Natural Product Library
HY-L115
-
Human Metabolite Library
HY-L123
-
Metabolic Enzyme Compound Library
HY-L146
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
PBCRBS Traditional Chinese Medicine Compound Library
HY-L193
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
Natural Product Diversity Scaffold Library
HY-L245
-
Tonifying Traditional Chinese Medicine Monomer Compound Library
HY-L246
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Ginsenoside F1
MoreVer todos los productos específicos de isoformas Endogenous Metabolite
More
Actividad biológica
|
CYP2 |
CYP3A4 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HL-60 | IC50 |
23.2 μM
Compound: 5
|
Cytotoxicity against human HL60 cells by MTT assay
Cytotoxicity against human HL60 cells by MTT assay
|
[PMID: 19926279] |
Ginsenoside F1 has been shown to flaunt anticancer, anti-aging, and antioxidant effects and has demonstrated competitive inhibition of CYP3A4 activity and weaker inhibition of CYP2D6 activity. The cell viabilities are 68% at the highest concentration of ginsenoside F1 (200 μM) in MTT assays[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 53963-43-2
-
Appearance Solid
-
Peso molecular 638.87
-
Fòrmula C36H62O9
-
Color White to off-white
-
SMILES
C[C@]([C@@](C[C@H]1O)([H])[C@]2(CC[C@@H]3O)C)(C[C@H](O)[C@@]2([H])C3(C)C)[C@]4([C@@]1([H])[C@]([C@@](CC/C=C(C)/C)(C)O[C@@H]([C@@H]([C@@H](O)[C@@H]5O)O)O[C@@H]5CO)([H])CC4)C
-
Synonyms
20(S)-Ginsenoside F1
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Nutrients
Protective Role of Ginsenoside F1-Enriched Extract (SGB121) in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). [Abstract]2025 Nov 25;17(23):3693. PMID: 41373985
Solvente y solubilidad
DMSO : ≥ 100 mg/mL (156.53 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.91 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.91 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
Glycosylation ability is assayed with overexpressed BSGT1 enzyme and F1. The reaction mixtures contain 100 μL of 0.5 mM F1 and 100 μL of 2.5 mM UDP-glucose and 800 μL of purified enzyme (final concentration at 0.1 mg/mL) (pH 7.0). The mixtures are incubated at 30°C for 24 h. Moreover, three groups of controls are incubated under the same conditions: (1) control 1 (C1) consists of Ginsenoside F1 with BSGT1; (2) control 2 (C2) consists of BSGT1 with UDP-glucose; and (3) control 3 (C3) consists of Ginsenoside F1 with UDP-glucose[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
B16BL6 cells are cultured in Dulbecco's modified Eagles medium supplemented with 10% fetal bovine serum and 1% Penicillin-Streptomycin at 37°C in a humidified 95% air/5% CO2 atmosphere. Cell viability is determined for Ginsenoside F1 and metabolite 1 using MTT conversion to formazan. Cells are seeded at a density of 1×105 cells/well in a 96-well plate, cultured for 24 h, and treated with various concentrations from 1 μM to 200 μM of Ginsenoside F1 and metabolite 1 for 5 d. Finally, 10 μL of MTT (5 mg/mL in PBS) is added to each well. Cells are incubated at 37°C for 3 h, and then DMSO (100 μL) is added to dissolve the formazan crystals. The absorbance is measured at 570 nm with the reference wavelength of 630 nm using an ELISA reader[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[2]
Six-week-old (17±1 g) male C57BL/6 mice and ApoE-/- mice with a C57BL/6 background are maintained in a temperature-controlled facility (temperature: 22±1°C; humidity: 60%) with a 14 h light/10 h dark cycle in conventional cages. Forty mice are randomly divided into four experimental groups (n=10/group): (I) C57BL/6 N mice, the control group; (II) ApoE-/- mice group; (III) ApoE-/- mice+ Ginsenoside F1 group; (IV) ApoE-/- mice+Probucol group. All mice are fed with a high fat diet (HFD, 0.3% cholesterol and 20% pork fat) for 8 weeks. Ginsenoside F1 (50 mg/kg/day, i.g.) and Probucol (2 g/kg, i.g.) are dissolved in carboxymethyl cellulose sodium (CMC-Na). Oral administration is given to mice every day for 8 weeks. The control and model groups receive the aseptic 0.5% CMC-Na treatment every day (i.g., 0.1 mL/10g) [2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (284 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Wang DD, et al. Rare ginsenoside Ia synthesized from F1 by cloning and overexpression of the UDP-glycosyltransferase gene from Bacillus subtilis: synthesis, characterization, and in vitromelanogenesis inhibition activity in BL6B16 cells. J Ginseng Res. 2018 Jan;42(1):42-49. [Content Brief]
[2]. Qin M, et al. Ginsenoside F1 Ameliorates Endothelial Cell Inflammatory Injury and Prevents Atherosclerosis in Mice through A20-Mediated Suppression of NF-kB Signaling. Front Pharmacol. 2017 Dec 22;8:953. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5653 mL | 7.8263 mL | 15.6526 mL | 39.1316 mL |
| 5 mM | 0.3131 mL | 1.5653 mL | 3.1305 mL | 7.8263 mL | |
| 10 mM | 0.1565 mL | 0.7826 mL | 1.5653 mL | 3.9132 mL | |
| 15 mM | 0.1044 mL | 0.5218 mL | 1.0435 mL | 2.6088 mL | |
| 20 mM | 0.0783 mL | 0.3913 mL | 0.7826 mL | 1.9566 mL | |
| 25 mM | 0.0626 mL | 0.3131 mL | 0.6261 mL | 1.5653 mL | |
| 30 mM | 0.0522 mL | 0.2609 mL | 0.5218 mL | 1.3044 mL | |
| 40 mM | 0.0391 mL | 0.1957 mL | 0.3913 mL | 0.9783 mL | |
| 50 mM | 0.0313 mL | 0.1565 mL | 0.3131 mL | 0.7826 mL | |
| 60 mM | 0.0261 mL | 0.1304 mL | 0.2609 mL | 0.6522 mL | |
| 80 mM | 0.0196 mL | 0.0978 mL | 0.1957 mL | 0.4891 mL | |
| 100 mM | 0.0157 mL | 0.0783 mL | 0.1565 mL | 0.3913 mL |
Ginsenoside F1 Related Classifications
HY-N0598 Related Classifications
Powered by Bioz